Weight loss medications such as Ozempic and Wegovy, categorized as GLP-1 agonists, have gained popularity but also raised concerns about severe side effects. Patients report issues such as nausea, erectile dysfunction, and vision changes. As more people use these medications, rarer side effects may emerge, prompting ongoing safety monitoring. Recent studies suggest links between the active ingredient semaglutide and conditions like NAION, which can lead to blindness, and show increased incidents of kidney problems and pancreatitis among users.
"Rarer side effects may emerge as more patients take these medicines in clinical practice, simply as a result of the much larger number of people treated than were included in the clinical development trials," noted Dr. Penny Ward.
Harvard researchers revealed a troubling link between semaglutide, the active ingredient in Ozempic and Wegovy, and non-arteritic anterior ischemic optic neuropathy (NAION), which threatens vision.
People with diabetes who take semaglutide were found to be four times more likely to develop NAION than the average person, indicating significant safety concerns.
Studies have shown that those taking GLP-1s have increased rates of kidney problems and pancreatitis, leading to investigations by the UK's medical regulator.
Collection
[
|
...
]